ESMO25: On helping patients with high unmet need, with Roberto Vieira & Adrian Jubb

This month, Corcept announced that the US FDA had accepted its New Drug Application (or NDA) for relacorilant, a selective glucocorticoid receptor antagonist, as a treatment for patients with platinum-resistant ovarian cancer.

Onsite at ESMO 2025, pharmaphorum spoke with Adrian Jubb, head of oncology and neurology clinical development at Corcept, and Roberto Vieira, president of oncology at Corcept, to discuss new data presented at the Congress this year, and in other serious disorders, including endogenous hypercortisolism.

You can watch this and other conversations from ESMO 2025 here.